Taysha Gene Therapies shares are trading higher after the company reported Q3 financial results. Also, Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $6 to $7.
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies' stock price increased following the release of their Q3 financial results. Additionally, Cantor Fitzgerald reaffirmed an Overweight rating and increased the price target for Taysha from $6 to $7.
November 15, 2023 | 7:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies' shares are up after positive Q3 financial results and an increased price target from Cantor Fitzgerald from $6 to $7.
The positive Q3 financial results indicate a strong performance by Taysha Gene Therapies, which is likely to instill investor confidence and drive the stock price up in the short term. Furthermore, the increased price target by Cantor Fitzgerald reinforces the positive outlook for the stock, suggesting that the stock is undervalued at its current price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100